Fisher Asset Management LLC Increases Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Fisher Asset Management LLC raised its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 25.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 494,924 shares of the company's stock after buying an additional 99,427 shares during the period. Fisher Asset Management LLC owned about 0.77% of Viridian Therapeutics worth $11,260,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of VRDN. Quest Partners LLC boosted its stake in Viridian Therapeutics by 344.0% in the second quarter. Quest Partners LLC now owns 6,056 shares of the company's stock valued at $79,000 after acquiring an additional 4,692 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Viridian Therapeutics in the third quarter valued at approximately $208,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Viridian Therapeutics by 24.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company's stock valued at $156,000 after purchasing an additional 2,359 shares during the last quarter. AlphaCentric Advisors LLC grew its position in Viridian Therapeutics by 108.3% in the second quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company's stock worth $163,000 after acquiring an additional 6,500 shares in the last quarter. Finally, Arizona State Retirement System raised its holdings in shares of Viridian Therapeutics by 14.7% during the 2nd quarter. Arizona State Retirement System now owns 13,178 shares of the company's stock valued at $171,000 after buying an additional 1,688 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on VRDN. The Goldman Sachs Group raised their price objective on Viridian Therapeutics from $25.00 to $31.00 and gave the company a "buy" rating in a research note on Thursday, September 12th. TD Cowen began coverage on shares of Viridian Therapeutics in a research report on Monday. They set a "buy" rating on the stock. Needham & Company LLC reiterated a "buy" rating and set a $38.00 target price on shares of Viridian Therapeutics in a report on Monday. BTIG Research upped their price target on Viridian Therapeutics from $56.00 to $61.00 and gave the stock a "buy" rating in a research note on Thursday, September 26th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $44.00 price objective on shares of Viridian Therapeutics in a report on Thursday, September 19th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, Viridian Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $36.33.

Insider Buying and Selling at Viridian Therapeutics

In other news, CEO Stephen F. Mahoney bought 21,400 shares of the firm's stock in a transaction on Friday, September 27th. The shares were bought at an average price of $23.33 per share, for a total transaction of $499,262.00. Following the purchase, the chief executive officer now owns 21,400 shares in the company, valued at approximately $499,262. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Thomas W. Beetham purchased 5,000 shares of the business's stock in a transaction on Friday, September 27th. The stock was acquired at an average price of $23.41 per share, with a total value of $117,050.00. Following the purchase, the chief operating officer now directly owns 6,000 shares in the company, valued at $140,460. This represents a 500.00 % increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 1,626,400 shares of company stock worth $30,616,312 in the last three months. 0.65% of the stock is currently owned by company insiders.

Viridian Therapeutics Stock Down 0.2 %

NASDAQ:VRDN traded down $0.04 on Thursday, reaching $21.87. 687,992 shares of the stock traded hands, compared to its average volume of 1,119,097. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $1.73 billion, a price-to-earnings ratio of -5.07 and a beta of 1.10. Viridian Therapeutics, Inc. has a 12 month low of $11.40 and a 12 month high of $27.20. The company's fifty day simple moving average is $22.75 and its 200 day simple moving average is $17.33.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.08 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. Equities analysts predict that Viridian Therapeutics, Inc. will post -4.04 EPS for the current fiscal year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.